Category: Commercialization
Payer and HTA negotiations stall without credible real-world evidence of value and the right patient segments.
Payer and HTA decisions increasingly demand credible real-world evidence of value, yet many teams lack the data and analytics to demonstrate it for the right patient segments. AI-driven real-world data analysis supports payer landscape analysis, value demonstration, and segmentation to strengthen market access strategy.
Payers and HTA bodies increasingly want evidence of how a therapy performs and who it helps in routine practice, not only in trials. AI and advanced analytics applied to real-world data — claims, EHRs, registries — help characterize disease burden, treatment patterns, and outcomes for specific patient segments, and can accelerate the descriptive and exploratory analysis that underpins a value story. The aim is to turn large, messy datasets into structured evidence about the right populations more quickly than manual analysis alone. Speed does not remove the need for rigor. Real-world analyses are vulnerable to bias and confounding, and evidence that payers will accept has to be designed and interpreted by people with health-economics and epidemiology expertise. AI can prepare data, surface patterns, and draft analyses; the study questions, methods, and conclusions remain human judgments, and no outcome should be claimed beyond what the data actually supports.
Begin with data fitness: ask how representative and well-documented the sources are for the population and question you care about, and how the tool handles gaps, coding differences, and linkage across datasets. Then scrutinize methodology — how it addresses confounding and study design, how transparent its analytic choices are, and whether the resulting evidence can be defended to a payer or HTA reviewer who will probe it. Because outputs may enter submissions and negotiations, examine whether methods align with recognized HEOR and regulatory expectations, how results are documented and reproduced, and how privacy and compliance are maintained across sensitive datasets. Weigh how well the tool fits your existing evidence-generation workflow and whether its analyses genuinely accelerate work once the necessary expert review is counted.
A practical entry point is to scope the tool to a single, well-understood question — one product, segment, or payer concern — and run its analysis alongside your usual approach, then compare the results against evidence and expert judgment you already trust. That shows whether the data and methods hold up, where outputs need correction, and whether the tool speeds credible evidence generation before anything it produces is used in a dossier or payer discussion.
Clinical trials show what happens in controlled settings, but payers and HTA bodies also want to understand how a therapy performs, who it reaches, and what value it delivers in routine practice across real populations. Real-world evidence helps address those questions and inform coverage, pricing, and access decisions, which is why demand for credible RWE keeps rising.
AI and advanced analytics can process large real-world datasets to characterize disease burden, treatment patterns, and outcomes for specific segments, and to accelerate the analyses behind a value story. It also supports the patient segmentation that helps demonstrate value for the right populations, turning fragmented data into structured evidence more quickly than manual work alone.
No. Real-world analyses can be undermined by bias and confounding, and evidence that withstands payer or HTA scrutiny has to be designed and interpreted by people with health-economics and epidemiology expertise. AI can prepare data and run analyses, but the study design, methods, and conclusions are human judgments, and no result should be presented beyond what the data supports.
Ask how representative and well-documented their data is for your question, how the tool handles gaps and linkage, and how it addresses confounding and study design. Then probe whether its methods align with recognized HEOR and regulatory expectations, how analyses are documented and reproduced, how privacy and compliance are maintained, and whether the evidence can be defended to a payer or HTA reviewer.
Intercept Pharmaceuticals worked with Komodo Health to apply its Healthcare Map real-world data to primary biliary cholangitis, supporting patient-journey and treatment-pattern analyses for its Ocaliva franchise.
Vendor: Komodo Health · press release (Komodo Health (Business Wire)) · 2022-11-10 — Partner: Intercept Pharmaceuticals
Panalgo, a Norstella company, launched LinQNotes and Ella AI to speed real-world data analysis that supports market access and commercial decision-making.
Vendor: Norstella · press release (Norstella) · 2025-05-14